In early results from a clinical trial, genetically engineered T cells eradicate leukemia cells and thrive. Two of three patients studied have been cancer-free for more than a year. A microscopic image shows two T cells binding to beads, depicted in yellow, that cause the cells to divide. After the beads are removed, the T cells are infused into cancer patients. (Dr. Carl June / Penn Medicine) By Eryn Brown, Los Angeles Times August 11, 2011 In a potential breakthrough in cancer research, scientists at the University of Pennsylvania have genetically engineered patients' T cells — a type of white blood cell — to attack cancer cells in advanced cases of a common type of leukemia. Two of the three patients who received doses of the designer T cells in a clinical trial have remained cancer-free for more than a year, the researchers said. Experts not connected with the trial said the feat was important because it suggested that T cells could be tweaked to kill a range of cancers, including ones of the blood, breast and colon. "This is a huge accomplishment — huge," said Dr. Lee M. Nadler, dean for clinical and translational research at Harvard Medical School, who discovered the molecule on cancer cells that the Pennsylvania team's engineered T cells target. Findings of the trial were reported Wednesday in two journals.[/p] source this isn't the whole article, just a bit under half of it, if you want to read the remainder follow the source.